Tela Bio, INC 8-K filings

TELA Bio reported a 4% revenue decline in Q2 2026 to $19.3 million and withdrew its full-year guidance, citing headwinds in OviTex PRS volumes and price mix.

TELA Bio, Inc. announces the immediate departure of CEO Antony Koblish and the appointment of Heather Getz as the new Chief Executive Officer and a director.

TELA Bio's stockholders approved an amendment to its 2019 Equity Incentive Plan, increasing the authorized shares by 3.5 million.

TELA Bio announced preliminary Q1 2026 revenue of $19 million and a significant restructuring of its Board of Directors.

TELA Bio, Inc. announced strong fourth quarter and full year 2025 financial results, driven by increased revenue and strategic operational improvements, alongside a new credit facility.

TELA Bio, Inc. received a Nasdaq deficiency letter for failing to maintain a minimum $1.00 bid price, initiating a 180-day compliance period.

TELA Bio, Inc. announced a new $70 million senior secured term loan facility and a registered direct offering expected to yield $11.9 million in net proceeds, while terminating its prior credit agreement with MidCap Financial Trust.

TELA Bio, a medical technology company, announced a 9% revenue increase for Q3 2025, revised full-year guidance, and secured a new $70 million credit facility.

TELA Bio, Inc. announced the appointment of William Plovanic, a seasoned healthcare equity research and medical technology executive, to its Board of Directors, expanding the board to seven members.

TELA Bio, Inc. announced the resignation of Lisa Colleran from its Board of Directors and the appointment of Dr. Betty Jo Rocchio as a new independent director.

TELA Bio, Inc. announced robust second quarter 2025 financial results, showcasing significant revenue growth and improved profitability metrics, while reiterating full-year guidance.

TELA Bio, Inc. announced the appointment of Jeffrey Blizard, a former board member and experienced medical device executive, as its new President, effective June 2, 2025.

TELA Bio, Inc. announced that its stockholders approved an amendment to increase authorized shares for its equity incentive plan by 3.5 million and elected Class III directors at its 2025 Annual Meeting.

TELA Bio announced a 12% year-over-year revenue increase for the first quarter of 2025, driven by strong demand for its OviTex products and the launch of larger-sized OviTex PRS.

TELA Bio announces the U.S. commercial launch of larger sizes of OviTex PRS Reinforced Tissue Matrix, designed for plastic and reconstructive surgery.

TELA Bio announced its Q4 and full-year 2024 financial results, highlighting revenue growth but also acknowledging challenges and providing revenue guidance for 2025.

TELA Bio announced record third-quarter revenue of $19.0 million, a 26% increase year-over-year, and reaffirmed its full-year 2024 revenue guidance.

TELA Bio, Inc. has entered into an underwriting agreement to sell 12 million shares of common stock and pre-funded warrants to purchase up to 5.8 million shares, expecting net proceeds of approximately $37.3 million.

TELA Bio reports preliminary Q3 2024 revenue of $19.0 million, a gross margin of approximately 68%, and implements cost-cutting measures expected to reduce operating expenses by $5.0 to $10.0 million annually.

TELA Bio announced an 11% year-over-year revenue increase for the second quarter of 2024, reaching $16.1 million, and reiterated its full-year revenue guidance of $74.5 million to $76.5 million.

TELA Bio has appointed Jeffrey Blizard to its Board of Directors, increasing the board size to seven members, effective June 4, 2024.

TELA Bio has appointed Greg Firestone as its new Chief Commercial Officer, effective May 20, 2024, following the termination of Peter Murphy.

TELA Bio announced a 39% year-over-year revenue increase for the first quarter of 2024, driven by strong demand for its OviTex products and expansion of its commercial operations.

TELA Bio has announced the U.S. commercial launch of OviTex IHR, a reinforced tissue matrix designed for laparoscopic and robotic-assisted inguinal hernia repair.

TELA Bio announced record fourth quarter and full year 2023 revenues, along with the U.S. commercial launch of LIQUIFIX hernia mesh fixation devices.

TELA Bio has sold the distribution rights for its NIVIS Fibrillar Collagen Pack to MiMedx for an initial payment of $5 million, with potential future payments up to $7 million based on sales performance.